The results showed that the total effective rate of CBMC in the combined group was greater than that in the single radiotherapy group (87.50% vs. 70.3%), the levels of tumor markers (CA125 and CEA) were significantly lower, and the levels of immune-related indices (CD3+, CD4+, and CD4+/CD8+) were significantly greater in the combined group. The gene discussed is CD8A; the disease is neoplasm.